Recent Articles in Cell & Gene Therapy

WestGene Biopharma reported that its mRNA therapeutic cancer vaccine, WGc-043, received dual IND approvals in China and the US. WGc-043 is the first mRNA vaccine for EBV-related cancers approved to start clinical trials in the two countries. According to WestGene, the approvals validate WestGene's expertise in core mRNA technologies such as delivery vectors and sequence design, while also advancing the commercialization of low-toxicity anti-tumor mRNA vaccines globally. More details....

Share this with colleagues:  

WuXi Biologics partnered with Medigene AG, a Munich Biotech, to design T cell receptor-guided T Cell Engagers (TCR-TCEs) aimed at difficult-to-treat tumors. The three-year effort will combine Medigen’s TCR expertise with WuXi’s anti-CD3 mAb, a TCE platform, and its proprietary bispecific antibody platform, WuXiBody™. Medigene wants to extend TCRs into new modalities, such as TCR-TCEs. The companies say the collaboration has the potential to become a multi-TCR program partnership. Wuxi Biologics is a Shanghai CRDMO focused on biologic drug development. More details....

Share this with colleagues:  

Huadong Medicine (Hangzhou) entered a $153 million pact for China commercialization rights to Immunopharm Technology’s IM19, a CAR T-cell immunotherapy that targets lymphoma. Huadong will pay $17.5 million upfront. IM19 injection has finished clinical trials for three indications, and Immunopharm expects to file for marketing approval before the end of the year. Immunopharm is a Beijing cell and gene therapy company. Huadong in-licenses China distribution rights for novel drugs. Previously, it acquired rights to commercialize a CARsgen CAR-T in China. More details....

Share this with colleagues:  

Sirnaomics, a Suzhou-Maryland siRNA company, has formed a JV, Sagesse Bio, with Gore Range Capital of Dallas to develop Sirnaomics’ RNAi products as aesthetic medicines. Sirnaomics will receive milestone payments of up to $33 million. It will eventually own a majority stake in Sagesse Bio worth $36 million after Gore Range completes a financing. Initially, Sagesse will start clinical evaluation of its candidate, SGY-101, a new designation of Sirnaomics’ lead siRNA candidate that has already started clinical trials for oncology and fat remodeling. More details....

Share this with colleagues:  

Suzhou Porton Advanced Solutions and Guangzhou Geneseed Biotech agreed to combine their circRNA gene therapy services and improve their offerings to CDMO clients. Porton Advanced will contribute its end-to-end cell and gene therapy CDMO service platform while Geneseed will add its core patented technologies in circRNA drug concept validation and process development. The two companies formed the collaboration to accelerate the development of novel circRNA therapies. More details....

Share this with colleagues: